Kazia Therapeutics Limited (KZIA)

Market Cap	13.15M
Revenue (ttm)	1.66M
Net Income (ttm)	-17.87M
Shares Out	4.35M
EPS (ttm)	-6.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,686
Open	3.110
Previous Close	3.090
Day's Range	2.885 - 3.160
52-Week Range	1.900 - 15.800
Beta	1.99
Analysts	Strong Buy
Price Target	20.00 (+562.25%)
Earnings Date	Jan 3, 2025

About KZIA

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA
• Website: https://www.kaziatherapeutics.com

Financial Performance

In 2024, Kazia Therapeutics's revenue was 2.48 million, an increase of 248000.00% compared to the previous year's 1,000. Losses were -26.78 million, 30.8% more than in 2023.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for KZIA stock is "Strong Buy" and the 12-month stock price forecast is $20.0.

Price Target

$20.0

(562.25% upside)

Analyst Consensus: Strong Buy